ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

EGFR/EGFRvIII Inhibitor WSD0922-FU

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Wayshine Biopharm.

Drug pageEGFR/EGFRvIII Inhibitor WSD0922-FU: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 25, 20242 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wayshine Biopharm22 open or runningphase 2since Aug 25, 2024Aug 25, 2024Jun 30, 2027phase 2 · NCT06631989

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2024First study: phase 2 study in EGFR Mutation Positive Advanced Non-Small Cell Lung CancerFirst studyNCT06631989 · 60 enrolled · China
  2. Sep 19, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07206498 · 48 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in EGFR Mutation Positive Advanced Non-Small Cell Lung CancerNCT06631989
  2. Oct 14, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07206498

TargetBeta

EGFR →read by rule
“A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07206498Carcinoma, Non-Small-Cell Lung · China2RecruitingOct 14, 202848
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer · China2Active, not recruitingJun 30, 202760

How it is read

Names in the registry

  • “WSD0922-FU”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.